
Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC
Findings from a subgroup analysis of the phase 3 CheckMate 9DW trial (NCT04039607) demonstrated that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) provided overall survival (OS) and overall response rate (ORR) benefits compared with …